Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Cited by (1,017)

Items 301–400 of 1,017

1. Intratumoral Immunotherapy for Early-stage Solid Tumors
   Wan Xing Hong, Sarah Haebe, Andrew Stephen Lee, Christoph Benedikt Westphalen, Jeffrey Allen Norton, Wen Jiang, Ronald Levy · 2020 · Clinical Cancer Research
2. Current issues and perspectives in PD-1 blockade cancer immunotherapy
   Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo · 2020 · International Journal of Clinical Oncology
3. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
   Keisuke Onoi, Yusuke Chihara, Junji Uchino, Takayuki Shimamoto, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama · 2020 · Journal of Clinical Medicine
4. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
   Ajjai Shivaram Alva, Pam K. Mangat, Elizabeth S. Garrett-Mayer, Susan Halabi, Damien Mikael Hansra, Carmen Julia Calfa, Maged F. Khalil, Eugene R. Ahn, Timothy Lewis Cannon, Pamela Ann Crilley et al. · 2021 · Journal of Clinical Oncology
5. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
   Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu et al. · 2022 · Journal of Clinical Oncology
6. A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates
   Penghui Zhang, Di Gao, Keli An, Qi Shen, Chen Wang, Yuchao Zhang, Xiaoshu Pan, Xigao Chen, Yifan Lyv, Cheng Cui et al. · 2020 · Nature Chemistry
7. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
   Carminia Maria Della Corte, Triparna Sen, Carl Michael Gay, Kavya Ramkumar, Lixia Diao, Robert J. Cardnell, B. Leticia Rodriguez, Catherine Allison Stewart, Vassiliki A. Papadimitrakopoulou, Laura Gibson et al. · 2020 · Journal of Thoracic Oncology
8. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
   Megan M. Tu, Hany A. Abdel-Hafiz, Robert T. Jones, Annie Jean, Katelyn J. Hoff, Jason E. Duex, Ana Chauca-Diaz, James C. Costello, Garrett Marc Dancik, Beth A. Jirón Tamburini et al. · 2020 · Communications Biology
9. Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
   Vikas, Praveen, Borcherding, Nicholas, Chennamadhavuni, Adithya, Garje, Rohan · 2020 · Frontiers in Oncology
10. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
    Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Célia Reynders, Thomas Lerho, Diane Bruyère, Alizée Lebeau, Coraline Radermecker et al. · 2021 · Journal for ImmunoTherapy of Cancer
11. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
    Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng · 2020 · Journal of Hematology & Oncology
12. Current and Future Clinical Applications of ctDNA in Immuno-Oncology
    Julia-Christina Stadler, Yassine Belloum, Benjamin Deitert, Mark Sementsov, Isabel Heidrich, Christoffer Gebhardt, Laura Keller, Klaus Pantel · 2021 · Cancer Research
13. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
    Gaurav Nayyar, Yaya Chu, Mitchell Stuart Cairo · 2019 · Frontiers in Oncology
14. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
    Briere, David M., Li, Shuai, Calinisan, Andrew, Sudhakar, Niranjan, Aranda, Ruth, Hargis, Lauren, Peng, David H., Deng, Jiehui, Engstrom, Lars D., Hallin, Jill et al. · 2021 · Molecular Cancer Therapeutics
15. Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer
    Αrgyris Τzouvelekis, Georgia Gomatou, Evangelos Bouros, Rodoula Trigidou, Vasilios Tzilas, Demosthenes E. Bouros · 2019 · CHEST Journal
16. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
    Mark Magdi Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih‐Hsin Yang, Steven Francis Powell, Ryan D. Gentzler, Renato G Martins, James P. Stevenson, Mehmet Altan et al. · 2020 · Journal of Thoracic Oncology
17. Chemo-Immunotherapy: A New Trend in Cancer Treatment
    Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González, Alejandra Martínez‐Pérez, Juan Pablo Rodrigo, Juana Maria Garcia-Pedrero, Segundo R. Gonzalez · 2023 · Cancers
18. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
19. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
20. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
    Margarita Majem, Óscar Juan, Amelia Insa, Noemı́ Reguart, José Manuel Trigo, Enric Carcereny, Rosario García‐Campelo, Yolanda García García, María Guirado, Mariano Provencio · 2018 · Clinical & Translational Oncology
21. Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
    Frohne, Christopher C., Llano, Ernesto M., Perkovic, Ashley, Cohen, Russell D., Luke, Jason J. · 2019 · Journal for ImmunoTherapy of Cancer
22. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
    Divyanshu Dubey, William S. David, Anthony A. Amato, Kerry Lynn Reynolds, Nathan F. Clement, Donald F. Chute, Justine Vanessa Cohen, Donald P. Lawrence, Meghan J. Mooradian, Ryan Joseph Sullivan et al. · 2019 · Neurology
23. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
    Eileen M. McGowan, Qimou Lin, Guocai Ma, Haibin Yin, Size Chen, Yiguang Lin · 2019 · Biomedicine & Pharmacotherapy
24. Emerging strategies to overcome resistance to third-generation EGFR inhibitors
    Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang, Weimin Li · 2022 · Journal of Hematology & Oncology
25. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
    Valsamo Anagnostou, Cheryl Ho, Garth Andrew Nicholas, Rosalyn Anne Juergens, Adrian Gerold Sacher, Andrea S. Fung, Paul Wheatley‐Price, Scott Andrew Laurie, Benjamin Philip Levy, Julie Renee Brahmer et al. · 2023 · Nature Medicine
26. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Sarah Cook, Vanessa Samuel, Daniel E. Meyers, Igor Stukalin, Ishjot Litt, Randeep S. Sangha, Don G. Morris, Daniel Yick Chin Heng, Aliyah Pabani, Michelle Liane Dean et al. · 2024 · JAMA Network Open
27. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
    Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott N. Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn et al. · 2020 · Journal of Thoracic Oncology
28. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
    Lise Lurienne, Julie Cervesi, Lola Duhalde, Jean de Gunzburg, Antoine Andremont, Gérard Zalcman, Renaud Buffet, Pierre-Alain Bandinelli · 2020 · Journal of Thoracic Oncology
29. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
    Samuel I. Kim, Christopher R. Cassella, Katelyn T. Byrne · 2021 · Frontiers in Immunology
30. Crizotinib in Patients With MET-Amplified NSCLC
    D. Ross Camidge, Gregory A. Otterson, Jeffrey William Clark, Sai‐Hong Ignatius Ou, Jared M. Weiss, Steven Ades, Geoffrey Ira Shapiro, Mark A. Socinski, Danielle A. Murphy, Umberto Conte et al. · 2021 · Journal of Thoracic Oncology
31. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
    Yixiang Gu, Ruifeng Yang, Yang Zhang, Miaomiao Guo, Kyle Takehiro, Ming Zhan, Linhua Yang, Hui Wang · 2025 · Molecular Biomedicine
32. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
    Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Marc Ryan Matrana, Matteo Rosellini, Luca Faloppi, Andrea Marchetti, Nicola Battelli, Francesco Massari · 2022 · Critical Reviews in Oncology/Hematology
33. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
    Xiong, Anwen, Wang, Lei, Chen, Jianhua, Wu, Lin, Liu, Baogang, Yao, Jun, Zhong, Hua, Li, Jie, Cheng, Ying, Sun, Yulan et al. · 2025 · The Lancet
34. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
    written on behalf of AME Lung Cancer Collaborative Group, Yangyang Xu, Bing Wan, Xi Chen, Ping Zhan, Yuan Zhao, Tianli Zhang, Hongbing Liu, Muhammad Zubair Afzal, Said Dermime et al. · 2019 · Translational Lung Cancer Research
35. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
    Lorenza Maria Landi, Federica D’Incà, Alain Jonathan Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta et al. · 2019 · Journal for ImmunoTherapy of Cancer
36. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
    Anna K. Nowak, Willem Joost Lesterhuis, Peey‐Sei Kok, Chris S. B. Brown, Brett G.M. Hughes, Deme John Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair Cook et al. · 2020 · The Lancet Oncology
37. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
    Gary Middleton, Kristian Brock, Joshua S. Savage, Rhys Mant, Yvonne Summers, John Conibear, Riyaz N.H. Shah, Christian H. H. Ottensmeier, Paul HS Shaw, Siow Ming Lee et al. · 2020 · The Lancet Respiratory Medicine
38. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
    James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rafael Rodríguez‐Cid, Li Zhang, Cheng‐Ta Yang et al. · 2024 · Journal of Clinical Oncology
39. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
    Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse, Ziyue Liu, Ahad Ali Sadiq, Robin T. Zon, Shadia Ibrahim Jalal, Goetz Hans Kloecker, Michael Williamson, Karen L. Reckamp et al. · 2020 · Cancer
40. Tumour mutational burden: clinical utility, challenges and emerging improvements
    Jan Budczies, Daniel N. Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor et al. · 2024 · Nature Reviews Clinical Oncology
41. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non–small cell lung cancer (NSCLC)
    Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael et al. · 2021 · Journal for ImmunoTherapy of Cancer
42. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
    Xiaofeng Chen, Xiaofeng Wu, Hao Wu, Yanhong Gu, Yang Washington Shao, Qianwen Shao, Feipeng Zhu, Xiao Li, Xiaofeng Qian, Jun X. Hu et al. · 2020 · Journal for ImmunoTherapy of Cancer
43. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
    Ravi Salgia, Rebecca R. Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler · 2021 · Cell Reports Medicine
44. Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
    Craig James Beavers, Jo E. Rodgers, Aaron Jacob Bagnola, Theresa M. Beckie, Umberto Campia, Katherine E. Di Palo, Tochi M. Okwuosa, Eugene R. Przespolewski, Dent Sj · 2022 · Circulation
45. Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
    Jin U. Kang, Chao Zhang, Wen‐Zhao Zhong · 2021 · 癌症：英文版
46. Barriers and opportunities in pancreatic cancer immunotherapy
    Yixin Ju, Dongzhi Xu, Miao-Miao Liao, Yutong Sun, Wen-dai Bao, Fan Yao, Li Ma · 2024 · npj Precision Oncology
47. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
    Manfred Dietel, Никита Александрович Савелов, Rubén Salanova, Patrick Micke, Gilbert Bigras, Toyoaki Hida, José Ramón Antúnez López, Birgit Guldhammer Skov, Georg Hutarew, Luz Fernanda Sua et al. · 2019 · Lung Cancer
48. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application
    Shuai Wang, Xiaohan Yuan, Saiqi Wang, Wen He Zhao, Xiaobing Chen, Bin Yu · 2021 · European Journal of Medicinal Chemistry
49. Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
    Zev A. Wainberg, Howard S. Höchster, Edward Jae-Hoon Kim, Ben George, Aparna Kaylan, Elena Gabriela Chiorean, David Michael Waterhouse, Martin Guiterrez, Aparna R. Parikh, Rishi Jain et al. · 2020 · Clinical Cancer Research
50. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Wolfgang Michael Brueckl, Joachim Hans Ficker, Gloria Zeitler · 2020 · BMC Cancer
51. Tracking Cancer Evolution through the Disease Course
    Chris Bailey, James R. Black, James L. Reading, Kevin Litchfield, Samra Turajlic, Nicholas McGranahan, Mariam Jamal‐Hanjani, Charles Swanton · 2021 · Cancer Discovery
52. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
    Giuseppe Viscardi, Antonino Carmelo Tralongo, Francesco Massari, Matteo Lambertini, Veronica Mollica, Alessandro Rizzo, Francesca Comito, Raimondo Di Liello, Salvatore Alfieri, Martina Imbimbo et al. · 2022 · European Journal of Cancer
53. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
    Yingyan Xue, Song Gao, Jingxin Gou, Tian Yin, Haibing He, Yanjiao Wang, Yu Xin Zhang, Xing Tang, Rong Wu · 2020 · Expert Opinion on Drug Delivery
54. Corticosteroids and Cancer Immunotherapy
    Rachel S. Goodman, Douglas Buckner Johnson, Justin Micah Balko · 2023 · Clinical Cancer Research
55. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
    Hari Menon, Rishab Ramapriyan, Taylor R. Cushman, Vivek Verma, Hans H. Kim, Jonathan E. Schoenhals, Semra Cemre Atalar, Uğur Selek, Stephen G. Chun, Joe Yujiao Chang et al. · 2019 · Frontiers in Immunology
56. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors
    Ioannis Kaffes, Frank Szulzewsky, Zhihong Chen, Cameron J. Herting, Ben Gabanic, José E. Velázquez Vega, Jennifer Shelton, Jeffrey M. Switchenko, James Ross, Leon McSwain et al. · 2019 · OncoImmunology
57. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
    Jing Liu, Zhihao Zhao, Nasha Qiu, Quan Zhou, Guowei Wang, Haiping Jiang, Ying Piao, Zhuxian Zhou, Jianbin Tang, Youqing Shen · 2021 · Nature Communications
58. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
    Deniz Can Güven, Enes Erul, Yunus Kaygusuz, Baran Akagündüz, Saadettin Kılıçkap, Raffaele De Luca, Alessandro Rizzo · 2023 · Supportive Care in Cancer
59. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
    Claudia Proto, Roberto Ferrara, Diego Signorelli, Giuseppe Lo Russo, Giulia Galli, Martina Imbimbo, Arsela Prelaj, Nicoletta Zilembo, Monica Ganzinelli, L.M. Pallavicini et al. · 2019 · Cancer Treatment Reviews
60. Emerging therapies for non-small cell lung cancer
    Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
61. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
    James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, James F. Spicer, James N. Arnold · 2019 · Frontiers in Immunology
62. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
    Oscar G. Arrieta, Feliciano Barrón, Laura Alejandra Ramírez-Tirado, Zyanya Lucía Zatarain-Barrón, Andrés Felipe Cardona, Diego A. Díaz-García, Masao Yamamoto Ramos, Beatriz Mota-Vega, Amir Carmona, Marco Polo Peralta Álvarez et al. · 2020 · JAMA Oncology
63. Mast Cells: A New Frontier for Cancer Immunotherapy
    Jake N. Lichterman, Sangeetha Meda Reddy · 2021 · Cells
64. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
    Kenneth K.W. To, Winnie Fong, William Chi Shing Cho · 2021 · Frontiers in Oncology
65. Personalized therapy for lung cancer: striking a moving target
    Suchita Pakkala, Suresh S. Ramalingam · 2018 · JCI Insight
66. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
    Biagio Ricciuti, Gonzalo Recondo, Liam Flinn Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette Marie Sholl et al. · 2020 · Clinical Cancer Research
67. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
    Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Francesco Ottavio Logullo, Matteo Rosellini, Andrea Marchetti, Luca Faloppi, Nicola Battelli, Francesco Massari · 2021 · Expert Opinion on Drug Metabolism & Toxicology
68. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
    Charu Aggarwal, Amy Prawira, Scott Joseph Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan Paul Zandberg et al. · 2022 · Journal for ImmunoTherapy of Cancer
69. Colorectal cancer immunotherapy-Recent progress and future directions
    Wen Zhao, Lujia Jin, Peng Chen, Dingchang Li, Wenxing Gao, Guanglong Dong · 2022 · Cancer Letters
70. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
71. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
    Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina‐Cerrillo et al. · 2023 · Cancer Immunology Immunotherapy
72. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
    Sayuri Miyauchi, Sangwoo S. Kim, John Pang, Kathryn Ann Gold, Jorge Silvio Gutkind, Joseph A. Califano, Loren K. Mell, Ezra E.W. Cohen, Andrew B. Sharabi · 2019 · Clinical Cancer Research
73. Cancer Immunotherapy: Beyond Checkpoint Blockade
    Michael Lawrence Dougan, Glenn Dranoff, Stephanie K. Dougan · 2018 · Annual Review of Cancer Biology
74. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
    Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya et al. · 2019 · International Journal of Clinical Oncology
75. In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence
    Quoc‐Viet Le, Juhan Suh, Jin Joo Choi, Gyu Thae Park, Sang Eun Lee, Gayong Shim, Yu‐Kyoung Oh · 2019 · ACS Nano
76. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
    Yunpeng Yang, Jiya Sun, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang et al. · 2021 · Journal of Thoracic Oncology
77. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
    Yi Wang, Yuya Wang, Yifei Ren, Qi Zhang, Ping Yi, Chunming Cheng · 2022 · Seminars in Cancer Biology
78. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
    Yelena Yuriy Janjigian, Eric Van Cutsem, Kei Muro, Zev A. Wainberg, Salah‐Eddin Al‐Batran, Woo Jin Hyung, Daniela Molena, Michelle Marcovitz, Dario Ruscica, Scott H. Robbins et al. · 2022 · Future Oncology
79. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    Howard A. Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Vladimirovich Breder, Jean‐Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz et al. · 2024 · The Lancet Oncology
80. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
    Jingjing Qu, Quanhui Mei, Lijun Chen, Jianying Zhou · 2020 · Cancer Immunology Immunotherapy
81. The clinical promise of immunotherapy in triple-negative breast cancer
    Praveen Vikas, Nicholas C. Borcherding, Weizhou Zhang · 2018 · Cancer Management and Research
82. Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi, Kazuhiko Nakagawa · 2019 · International Journal of Clinical Oncology
83. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity
    Lili Zhang, Kerry Lynn Reynolds, Alexander Richard Lyon, Nicolas L. Palaskas, Tomas G. Neilan · 2021 · JACC CardioOncology
84. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
    Ilke Tunali, Jhanelle E. Gray, Jin Qi, Mahmoud A. Abdalah, Daniel K. Jeong, Albert Güveniş, Robert J. Gillies, Matthew B. Schabath · 2019 · Lung Cancer
85. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
    Jhanelle E. Gray, Andreas Nicholas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott Joseph Antonia, Michael Rahman Shafique, Hong Zheng, Wenjie Dai, James Joseph Saller et al. · 2019 · Clinical Cancer Research
86. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
    Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, Fabiana Letizia Cecere, Sara Pilotto, Vieri Scotti et al. · 2020 · European Journal of Cancer
87. An update on the immune landscape in lung and head and neck cancers
    Jennifer Wilkinson Carlisle, Conor Ernst Steuer, Taofeek Kunle Owonikoko, Nabil F. Saba · 2020 · CA A Cancer Journal for Clinicians
88. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
    Junyan Li, Yu‐Pei Chen, Ying‐Qin Li, Na Liu, Jun Ma · 2021 · Molecular Cancer
89. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
    Catherine R. Sears, Tobias Peikert, Jennifer D. Possick, Jarushka Naidoo, Mizuki Nishino, Sandip Pravin Patel, Philippe Camus, Mina Gaga, Edward B. Garon, Michael K. Gould et al. · 2019 · American Journal of Respiratory and Critical Care Medicine
90. Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer
    David Michael Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Weiwei Gao, Yong Yuan, John Hartman, Sumati A. Rao, Solomon James Lubinga, David Dean Stenehjem · 2021 · Lung Cancer
91. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
    Dongsheng Yue, Wenxiang Wang, Hongxu Liu, Qixun Chen, Chun Chen, Lunxu Liu, Peng Zhang, Guofang Zhao, Fan Yang, Guang Han et al. · 2024 · The Lancet Respiratory Medicine
92. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
    Lin, Jessica J., Chin, Emily, Yeap, Beow Y., Ferris, Lorin A., Kamesan, Vashine, Lennes, Inga T., Sequist, Lecia V., Heist, Rebecca S., Mino-Kenudson, Mari, Gainor, Justin F. et al. · 2019 · Journal of Thoracic Oncology
93. The emergence of drug resistance to targeted cancer therapies: Clinical evidence
    Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos · 2019 · Drug Resistance Updates
94. Advances and prospects of biomarkers for immune checkpoint inhibitors
    Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, Shao‐Chun Wang, Mien‐Chie Hung · 2024 · Cell Reports Medicine
95. Intratumoral Immunotherapy: From Trial Design to Clinical Practice
    Stéphane Champiat, Lambros Tselikas, Siham Farhane, Thibault Raoult, Matthieu Texier, Émilie Lanoy, Christophe Massard, Caroline Robert, Samy Ammari, Thierry de Baère et al. · 2020 · Clinical Cancer Research
96. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations
    Charlotte R. Bell, Victoria S. Pelly, Agrin Moeini, Shih‐Chieh Chiang, Eimear Flanagan, Christian P. Bromley, C I Clark, Charles H. Earnshaw, Maria A. Koufaki, Eduardo Bonavita et al. · 2022 · Nature Communications
97. Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
    Mao Lin, Haihua Luo, Shuzhen Liang, Jibing Chen, Aihua Liu, Lizhi Niu, Yong Jiang · 2020 · Journal of Clinical Investigation
98. PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death
    Max Jing Rui Tham, Maria V. Babak, Wee Han Ang · 2020 · Angewandte Chemie International Edition
99. Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
    Misty Dawn Shields, Julian Andres Marin-Acevedo, Bruna Pellini · 2021 · American Society of Clinical Oncology Educational Book
100. DNA Nanotechnology‐Based Biosensors and Therapeutics
     Luyao Shen, Pengfei Wang, Yonggang Ke · 2021 · Advanced Healthcare Materials